The Economic Times
English EditionEnglish Editionहिन्दीગુજરાતીमराठीবাংলাಕನ್ನಡമലയാളംதமிழ்తెలుగు
| 04 July, 2024, 06:53 AM IST | Today's ePaper
Monsoon Offer is Live
Search
+
Business News›themis medicare ltd q4 results
    SEARCHED FOR:

    THEMIS MEDICARE LTD Q4 RESULTS

    Do Dr Lal Pathlabs' results indicate a turnaround for the sector? 4 stocks from diagnostic space, 3 with upside potential of up to 31%

    Some sectors have a company which can be called as the bell weather of that sector and that is why its results of that company probably are indicative of what is happening in the sector. In case of the diagnostic, it is probably the Dr Lals path labs which would fit the criteria, it has national presence, large network, present in both physical and digital segment. So when the quarterly numbers come and they show improvement on many fronts then probably it is time to have a look at them more seriously and see if there is a possible turnaround building in the sector. This became even more important because these stocks had gained extremely high valuation and also popularity in terms of both retail and institutional participation. But then for close to two years, they have been a strong under performer in a strong bull market. Does this result mean that finally in terms of price war for customer acquisition over and now the valuation readjustment will start in the upward direction.

    The penicillin war: India's journey from self-sufficiency to dependence on China

    After India lost its dominance in making penicillin, a drought of three decades is coming to an end. The drug – which forms the base for a raft of extremely potent antibiotics – is part of the govt’s aggressive push for self-sufficiency in critical areas. Will the plan to claw back to the glorious past work?

    Painful readjustment of valuations over? 4 stocks from diagnostics sector with upside potential of up to 31%

    In the last four years, many sectors have made a comeback. However, there are few, who have probably a full life cycle in this short period of time. From all the love on the street which made them touch dizzy heights of valuations. Then a realization that the street is paying too much for them. It is about the diagnostic sector. From being part of a star portfolio manager tops picks, to him admitting that he made a mistake. Diagnostic stocks have seen a cycle. There is another side to the story. Every sector which goes through such cycles in the short term, tends to see a recovery. The only difference is the recovery time, both of the business and getting recognised once again by the street. So, these stocks will make a comeback, whether it happens in one quarter or after years is the question. But one thing is for sure, that if you are a long term investor, don't be in a hurry to get out of the sector.

    For medium to long term investors: 4 midcap stocks with right ratio matrix and upside potential of up to 30%

    It is never easy to find a good stock. Not for any other reason, but the fact of “ good stock” is an open ended term. For some consideration of calling something a “good stock” is largely how the price of the stock behaves in different market conditions. Like does it fall less in bearish markets and moves up faster in bullish markets. For some a stock which is available at cheaper valuations, could be a good stock. So, each to its own. But when it comes to business and management , there is only one thing “good business” and “ good management” which has no open ended interpretation. A business which generates good cash flows and has large market size to grow and for management a clean balance sheet and good corporate governance.

    Stay bullish, just add some checks and balances : 4 midcap stocks with upside potential of up to 36%

    In the last few trading sessions, the way market breadth has panned out in the mid-cap segment it is very clear that demand for midcap paper is still very high. If one looks at the reaction of the street to a positive surprise in Q4 results coming from a mid-cap company, it is very clear there is still lots of money which is ready to move into midcap stocks. While good results will bring some moderation in valuations, but on an overall basis, the valuations are still at the higher end. But as the liquidity support continues, there is no point in fighting it. The only thing that needs to be done, that while buy the stocks, be more selective and have a long term perspective. Don't panic if tomorrow due to what the US Fed does or anything happening in the Middle east, there is a correction. That will only happen, if one has done his or her homework before buying the stocks.

    Anand Rathi initiates coverage on 6 hospital stocks with upside potential of up to 25%

    Anand Rathi initiates coverage on 6 hospital stocks, recommending 'buy' for Max Healthcare, Rainbow Children’s Medicare, KIMS, and Jupiter Life-Line Hospitals, while suggesting 'hold' for Global Health (MEDANTA) and Narayana Hrudayalaya. They cite India's healthcare market potential, driven by demographic changes and non-communicable diseases, forecasting 15% CAGR to Rs 7.7 lakh crore by FY25.

    The Economic Times
    BrowseCompanies:
    BACK TO TOP